Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br Funding This work was supported by the National
2020-11-09
Funding This work was supported by the National Natural Science Foundation of China (grant number 81671411); Beijing Natural Science Foundation (grant number 7162062); Beijing Nova Program Interdisciplinary Cooperation Projects (grant number Z161100004916045); Beijing Municipality Health Technolo
-
br Other pathways involved in the preventive
2020-11-09
Other pathways involved in the preventive and therapeutic potential of flavonoids in neurodegenerative diseases Rather than the induction of MAPK/ERK pathway, flavonoids actively modulate other critical intracellular neuronal survival and death protein kinases pathways, more importantly PI3K/Akt,
-
br Materials and methods br Results br
2020-11-09
Materials and methods Results Discussion DUSP1 is a member of the subfamily of the Dusl specific phosphatases (DUSPs). High levels of DUSP1 observed in lung, liver and placenta, and low levels have been found in the 2211 and kidney. DUSP1 has been shown to be elevated in various diseases [1
-
br Conclusion br Acknowledgments This
2020-11-09
Conclusion Acknowledgments This work was supported by Progetto PON - “Ricerca e Competitività 2007–2013” - PON01_01802: “Sviluppo di molecole capaci di modulare vie metaboliche intracellulari redox-sensibili per la prevenzione e la cura di patologie infettive, tumorali, neurodegenerative e lor
-
In some cases more than one CYP enzyme
2020-11-09
In some cases, more than one CYP450 enzyme may be involved in the metabolism of a drug, and an Eadie–Hofstee plot is usually more reliable for assessing the involvement of multiple MC1568 sale (Bu, 2006). Therefore, we first plotted the Eadie–Hofstee curves and observed their shape to determine the
-
Our approach including the characterization of histone
2020-11-09
Our approach, including the characterization of histone modifications in scarce NK subsets, allowed us to identify super-enhancers, which associate with genes endowing a given cell type with its unique identity (Hnisz et al., 2013). Especially intriguing were SEs with distinct activities in NK subse
-
Given the link between E s autoimmunity and antitumor immuni
2020-11-09
Given the link between E3s, autoimmunity, and antitumor immunity, it Cy5 azide synthesis is reasonable to assume that, similar to other ICBs, IRAEs may limit the clinical use of E3-targeting therapies – further stressing the need to better understand the underlying mechanisms of these unwanted effe
-
Beyond phosphorylation cancer cells may
2020-11-06
Beyond phosphorylation, cancer Calcipotriol may alter pyrimidine biosynthesis through the activation of the proto-oncogenic transcription factor MYC. MYC is a master regulator of many different pathways and has significant influence on the expression of nucleotide metabolism genes. Previous studies
-
br Conclusion br Acknowledgments br Introduction Arsenic As
2020-11-06
Conclusion Acknowledgments Introduction Arsenic (As) is one of the most toxic metals derived from the natural environment in soil, air and well water. It has two oxidative states: a trivalent form, arsenite, and a pentavalent form, arsenate. The inorganic As is more toxic than organic As. A
-
Alvocidib flavopiridol is a piperidine chromenone
2020-11-06
Alvocidib (flavopiridol) is a piperidine-chromenone derivative (Fig. 6D) that is not FDA approved, but is in clinical trials for breast, endometrial, and several other cancers and hematological malignancies (Table 4) [[100], [101], [102], [103], [104]]. This drug targets CDK9 (IC50 = 3.2 nM) and CDK
-
Since clinical studies mostly involved cases that used MPA d
2020-11-06
Since clinical studies mostly involved cases that used MPA, data from studies that examined other types of progestogens are very limited. While the WHI study examined the combination of conjugated equine estrogens plus MPA [1], the Million Women Study [2] that also demonstrated an increased risk of
-
Enlarging the ligand binding pocket by reduction of the size
2020-11-06
Enlarging the ligand-binding pocket by reduction of the size of the residue F435 switched DES to an agonist indicating that F435 is involved in mediating the antagonistic effect of DES (Fig. 7E) [13]. The conformation of the smaller side chain of L435 was either not altered by DES or was too small t
-
The interaction of EPAC with Rim has
2020-11-06
The interaction of EPAC2 with Rim1 has an important role in regulating neurotransmitter release. In addition, a recent EPAC2 knockout mice model study provides evidence that EPAC2 promotes transmitter release by maintaining the readily releasable pool (RRP) at mossy fiber (MF) synapses in the hippoc
-
br Substrate Specificity Discrimination and Binding Energy
2020-11-06
Substrate Specificity, Discrimination, and Binding Energy In 50014 to catalytic efficiency, which can be gauged in reference to an absolute scale of ‘catalytic perfection’ 10, 11, specificity is a relative concept because it requires comparison between given alternative substrates. In fact, spec
-
Preliminary studies suggest that dimerization of the
2020-11-06
Preliminary studies suggest that dimerization of the AT1 receptor occurred during the biosynthesis in the endoplasmic reticulum before surface expression [27,40], which may explain the presenece of these Wnt agonist 1 before the addition of any ligand. Our results showed that the presence of Ang I
14532 records 752/969 page Previous Next First page 上5页 751752753754755 下5页 Last page